Therapeutic drug monitoring of voriconazole for treatment and prophylaxis of invasive fungal infection in children

Voriconazole therapeutic drug monitoring is not consistently recommended due to its high interpatient and intrapatient variability. Here, we aimed to describe our experience with voriconazole for treatment and prophylaxis of invasive fungal infections in paediatric patients. A fully validated high-performance liquid chromatography-mass spectrometry method was used to quantify voriconazole concentration in plasma, at the end of dosing interval. A high interindividual variability was shown. We enrolled 237 children, 83 receiving intravenous and 154 oral voriconazole. A positive correlation between drug dose and drug plasma exposure was observed. Considering intravenous route, patients with higher serum creatinine had higher voriconazole concentrations; a positive correlation was found among drug exposure and age. Sex significantly influenced drug levels: males had higher median drug concentrations than females (P < 0.001). Close voriconazole pharmacokinetics monitoring should help individualize antifungal therapy for children.

[1]  Voriconazole , 2019, Reactions Weekly.

[2]  Hongwei Zhao,et al.  Effects of cytochrome P450 3A4 and non-genetic factors on initial voriconazole serum trough concentrations in hematological patients with different cytochrome P450 2C19 genotypes , 2017, Xenobiotica; the fate of foreign compounds in biological systems.

[3]  L. Pagano,et al.  ECIL-6 guidelines for the treatment of invasive candidiasis, aspergillosis and mucormycosis in leukemia and hematopoietic stem cell transplant patients , 2016, Haematologica.

[4]  Krista L. Niece,et al.  In Vitro Study of the Variable Effects of Proton Pump Inhibitors on Voriconazole , 2015, Antimicrobial Agents and Chemotherapy.

[5]  D. Denning,et al.  British Society for Medical Mycology best practice recommendations for the diagnosis of serious fungal diseases. , 2015, The Lancet. Infectious diseases.

[6]  J. Xing,et al.  Efficacy and safety of voriconazole and CYP2C19 polymorphism for optimised dosage regimens in patients with invasive fungal infections. , 2014, International journal of antimicrobial agents.

[7]  A. McLachlan,et al.  Understanding variability with voriconazole using a population pharmacokinetic approach: implications for optimal dosing. , 2014, The Journal of antimicrobial chemotherapy.

[8]  J. Xing,et al.  Identification of factors influencing the pharmacokinetics of voriconazole and the optimization of dosage regimens based on Monte Carlo simulation in patients with invasive fungal infections. , 2014, The Journal of antimicrobial chemotherapy.

[9]  M. Hoenigl,et al.  Potential Factors for Inadequate Voriconazole Plasma Concentrations in Intensive Care Unit Patients and Patients with Hematological Malignancies , 2013, Antimicrobial Agents and Chemotherapy.

[10]  F. D. De Rosa,et al.  Development and validation of a new method to simultaneously quantify triazoles in plasma spotted on dry sample spot devices and analysed by HPLC-MS. , 2012, The Journal of antimicrobial chemotherapy.

[11]  T. Egberts,et al.  Highly Variable Plasma Concentrations of Voriconazole in Pediatric Hematopoietic Stem Cell Transplantation Patients , 2012, Antimicrobial Agents and Chemotherapy.

[12]  P. G. Choe,et al.  The effect of therapeutic drug monitoring on safety and efficacy of voriconazole in invasive fungal infections: a randomized controlled trial. , 2012, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[13]  T. Buclin,et al.  Challenging recommended oral and intravenous voriconazole doses for improved efficacy and safety: population pharmacokinetics-based analysis of adult patients with invasive fungal infections. , 2012, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[14]  A. McLachlan,et al.  Multicenter Study of Voriconazole Pharmacokinetics and Therapeutic Drug Monitoring , 2012, Antimicrobial Agents and Chemotherapy.

[15]  M. Karlsson,et al.  Integrated Population Pharmacokinetic Analysis of Voriconazole in Children, Adolescents, and Adults , 2012, Antimicrobial Agents and Chemotherapy.

[16]  D. Colantonio,et al.  Therapeutic Drug Monitoring of Voriconazole in Children , 2012, Therapeutic drug monitoring.

[17]  C. Elie,et al.  Therapeutic Drug Monitoring of Voriconazole After Intravenous Administration in Infants and Children With Primary Immunodeficiency , 2011, Therapeutic drug monitoring.

[18]  P. Troke,et al.  Observational Study of the Clinical Efficacy of Voriconazole and Its Relationship to Plasma Concentrations in Patients , 2011, Antimicrobial Agents and Chemotherapy.

[19]  B. Damle,et al.  Review of the basic and clinical pharmacology of sulfobutylether-beta-cyclodextrin (SBECD). , 2010, Journal of pharmaceutical sciences.

[20]  F. D. De Rosa,et al.  Development, Validation, and Routine Application of a High-Performance Liquid Chromatography Method Coupled with a Single Mass Detector for Quantification of Itraconazole, Voriconazole, and Posaconazole in Human Plasma , 2010, Antimicrobial Agents and Chemotherapy.

[21]  Y. Fujimoto,et al.  Pharmacokinetic–pharmacodynamic analysis of voriconazole in Japanese patients with hematological malignancies , 2008, European Journal of Clinical Microbiology and Infectious Diseases.

[22]  Thierry Buclin,et al.  Voriconazole therapeutic drug monitoring in patients with invasive mycoses improves efficacy and safety outcomes. , 2008, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[23]  L. Gordon,et al.  Breakthrough fungal infections after allogeneic hematopoietic stem cell transplantation in patients on prophylactic voriconazole , 2007, Bone Marrow Transplantation.

[24]  N. Wood,et al.  Effect of food on the pharmacokinetics of multiple-dose oral voriconazole. , 2003, British journal of clinical pharmacology.

[25]  N. Ampel,et al.  American Thoracic Society Documents an Official American Thoracic Society Statement: Treatment of Fungal Infections in Adult Pulmonary and Critical Care Patients Contents Introduction Methods Antifungal Agents: General Considerations Polyenes Triazoles Echinocandins Treatment of Fungal Infections Hi , 2022 .

[26]  G. Thompson,et al.  Update on the optimal use of voriconazole for invasive fungal infections , 2011 .

[27]  R. Jelliffe,et al.  Voriconazole pharmacokinetics and pharmacodynamics in children. , 2010, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.